Exosome Diagnostics Publishes a Study Demonstrating Superior Performance of ExoLution™ Plus Liquid Biopsy Platform in Lung Cancer
December 19, 2017 07:51 ET | Exosome Diagnostics
Waltham, MA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., recently published a study in the Journal Annals of Oncology, of EGFR Liquid Biopsy detection in patients with Non-Small...
Qu Biologics.png
Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer
November 28, 2017 12:43 ET | Qu Biologics
VANCOUVER, British Columbia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Global Lung Cancer A
Global Lung Cancer Awareness Month Coalition Kicks-Off 2017 Awareness Month
November 06, 2017 15:13 ET | Lung Cancer Awareness Month Coalition
WASHINGTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- The Lung Cancer Awareness Month Coalition (LCAMC), a group of more than twenty research and advocacy organizations from around the world focused on...
Logo.jpg
New Study Reports Favorable Results for Intuitive Surgical’s Flexible Robotics Platform
November 02, 2017 09:00 ET | Intuitive Surgical, Inc.
SUNNYVALE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Results from the first clinical study evaluating a new flexible robotics platform under development by Intuitive Surgical were presented at the...
Vaccinex logo
Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)
October 26, 2017 10:23 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Vaccinex Inc. today announced the dosing of the first patient in a Phase Ib/II study of VX15/2503, an investigational humanized anti-semaphorin 4D...
BluePrint Phase 2 De
BluePrint Phase 2 Demonstrates Digital Pathology Review Equivalent to Glass Slides
October 17, 2017 21:45 ET | Histogenex LLC
YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- The BluePrint Phase 2 committee today presented its findings comparing five PD-L1 IHC assays at the International Association for the Study of Lung...
IASLC-Logos-HZ-tag - Copy - Copy.jpg
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions
October 17, 2017 02:08 ET | IASLC
YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today’s press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured...
IASLC-Logos-HZ-tag - Copy - Copy.jpg
World Conference on Lung Cancer Monday Press Conference: Dangers of Smoking and Lung Cancer Intervention Research
October 16, 2017 02:40 ET | IASLC
YOKOHAMA, Japan, Oct. 16, 2017 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC), the...
IASLC-Logos-HZ-tag - Copy - Copy.jpg
World Conference on Lung Cancer Sunday Press Conference: Introducing New Awards and Global Guidelines
October 15, 2017 03:25 ET | IASLC
YOKOHAMA, Japan, Oct. 15, 2017 (GLOBE NEWSWIRE) -- The first press briefing at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC)...
IASLC-Logos-HZ-tag - Copy - Copy.jpg
The International Association for the Study of Lung Cancer Announces Abstract Selections for the 18th World Conference on Lung Cancer
September 07, 2017 14:00 ET | IASLC
DENVER, Sept. 07, 2017 (GLOBE NEWSWIRE) -- The International Association for the Study of Lung Cancer (IASLC) announced today the abstract selections for the 18th World Conference on Lung Cancer...